Nephrol Dial Transplant (2003) 18: 924-930
© 2003 European Renal Association-European Dialysis and Transplant Association
Carbonyl stress induced by intravenous iron during haemodialysis
1 Eliachar Research Laboratory, 2 Nephrology Unit and 3 Biochemistry Laboratory, Western Galilee Hospital, Nahariya and 4 Bruce Rappaport School of Medicine, Technion, Haifa, Israel
Background. Anaemic haemodialysis (HD) patients are treated with erythropoietin and intravenous iron for effective erythropoiesis. Since iron is a potent inducer and aggravator of pre-existing oxidative processes in HD patients, this study was aimed to evaluate the acute in vivo effect of two recommended iron doses on protein oxidation during the HD session.
Methods. Iron gluconate was intravenously administered to HD patients in doses of 62.5 or 125 mg per session. A dialysis session without iron administration served as a control for each patient. Carbonylated fibrinogen and iron profile parameters were monitored before and after each session. Plasma carbonylated fibrinogen levels from healthy subjects and HD patients before dialysis were compared. Protein associated carbonyls were identified in plasma by derivatization with 2,4-dinitrophenylhydrazine followed by western analysis and were quantified by densitometry.
Results. HD patients on maintenance iron showed elevated carbonylated fibrinogen compared with healthy subjects. During a HD session, carbonyls on fibrinogen further increased when 125 mg iron gluconate was administered, but no changes were detected with 62.5 mg iron gluconate or in the absence of iron. The changes in carbonylated fibrinogen during dialysis showed a significant linear correlation with the calculated values of transferrin saturation and free transferrin.
Conclusions. The significant acute increase in carbonylated fibrinogen with 125 mg iron gluconate suggests that this iron dose should be used with caution. As fibrinogen is highly susceptible to iron-induced oxidation in vivo, it may serve as a marker reflecting acute iron oxidative damage and as a tool in refinement of the existing clinical dose guidelines for intravenous iron therapy.
Keywords: carbonyl stress; fibrinogen; haemodialysis; intravenous iron therapy; iron gluconate; oxidative stress
Correspondence and offprint requests to: Batya Kristal, Head of Nephrology and Hypertension Department, Western Galilee Hospital, Nahariya, Israel 22100. Email: krisdl{at}naharia.health.gov.il
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. N. Ibrahim, R. N. Foley, R. Zhang, D. T. Gilbertson, and A. J. Collins Parenteral Iron Use: Possible Contribution to Exceeding Target Hemoglobin in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Spormann, F. W. Albert, T. Rath, H. Dietrich, F. Will, J.-P. Stockis, G. Eisenbrand, and C. Janzowski Anthocyanin/Polyphenolic-Rich Fruit Juice Reduces Oxidative Cell Damage in an Intervention Study with Patients on Hemodialysis Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3372 - 3380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hayat Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease Clin. Med. Res., December 1, 2008; 6(3-4): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-L. Kuo, S.-C. Hung, Y.-H. Wei, and D.-C. Tarng Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1817 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. de Vecchi, C. Novembrino, S. Lonati, S. Ippolito, and F. Bamonti Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1709 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Maruyama, M. Nakayama, K. Yoshimura, H. Nakano, H. Yamamoto, K. Yokoyama, and B. Lindholm Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1407 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]
|
|
|
|
|
|
G. Guz, G. L. Glorieux, R. De Smet, M.-A. F. Waterloos, R. C. Vanholder, and A. W. Dhondt Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2834 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke and Z. A. Massy Intravenous Iron: How Much Is Too Much? J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2833 - 2835. [Full Text] [PDF]
|
|
|
|
|
|
R. Michelis, S. Sela, and B. Kristal Intravenous iron-gluconate during haemodialysis modifies plasma {beta}2-microglobulin properties and levels Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1963 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Aronoff Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S99 - S106. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Van Wyck Labile Iron: Manifestations and Clinical Implications J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S107 - S111. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sela, R. Mazor, M. Amsalam, C. Yagil, Y. Yagil, and B. Kristal Primed Polymorphonuclear Leukocytes, Oxidative Stress, and Inflammation Antecede Hypertension in the Sabra Rat Hypertension, November 1, 2004; 44(5): 764 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borawski, J. Gozdzikiewicz, P. Abramowicz, B. Naumnik, and M. Mysliwiec Endothelial Injury Markers With High-dose IntravenousIron Therapy in Renal Failure Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 403 - 406. [Abstract] [PDF]
|
|
|
|
|
|
D. Van Wyck, J. Anderson, and K. Johnson Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol. Dial. Transplant., March 1, 2004; 19(3): 561 - 565. [Abstract] [Full Text] [PDF]
|
|